Microcarriers encapsulating COL1A1 mRNA-loaded nanovesicles for skin photoaging treatment.

Xiang Lin, Anne M Filppula, Luoran Shang, Hongbo Zhang, Dexuan Wang

Abstract read

In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiang LinDepartment of Pediatrics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325027, China.

Anne M FilppulaPharmaceutical Sciences Laboratory, Department of Natural and Health Sciences, Åbo Akademi University, Turku, 20520, Finland.

Luoran ShangShanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, and the Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology, Institutes of Biomedical Sciences), Fudan University, Shanghai, 200032, China.

Hongbo ZhangPharmaceutical Sciences Laboratory, Department of Natural and Health Sciences, Åbo Akademi University, Turku, 20520, Finland.

Dexuan WangDepartment of Pediatrics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325027, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles have shown great potential in treating ultraviolet (UV)-induced skin photoaging. However, effective delivery of these bioactive agents to achieve long-term therapeutic effects remains a significant challenge. In this study, we have developed recombinant human collagen (RHC)-based microcarriers loaded with native exosomes as well as Collagen type I alpha 1 chain (COL1A1) mRNA-encapsulating nanovesicles (Emvs) to treat skin photoaging. The microcarriers mitigated UV-induced cellular senescence in HaCaT cells, as evidenced by reduced oxidative stress, decreased apoptosis, and attenuation of senescence-associated markers. In the animal model, the microcarriers not only attenuated wrinkle formation, but also promoted type I collagen deposition in UV-damaged skin. These results together with the demonstrated biocompatibility highlight the potential of the microcarrier delivery system in photoaging treatment.

Indexed as

MicrocarriersMicrofluidic electrospraymRNA deliveryNanovesiclesPhoto-aging

Identifiers

PMID42028282

DOI10.1016/j.mtbio.2026.103126

PMCPMC13101773

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.